| Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial RT Lester, P Ritvo, EJ Mills, A Kariri, S Karanja, MH Chung, W Jack, ... The Lancet 376 (9755), 1838-1845, 2010 | 1637 | 2010 |
| The independent contribution of executive functions to health related quality of life in older women JC Davis, CA Marra, M Najafzadeh, T Liu-Ambrose BMC geriatrics 10, 1-8, 2010 | 283 | 2010 |
| Cost-effectiveness of novel regimens for the treatment of hepatitis C virus M Najafzadeh, K Andersson, WH Shrank, AA Krumme, OS Matlin, ... Annals of internal medicine 162 (6), 407-419, 2015 | 257 | 2015 |
| Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPRISE study E Patorno, A Pawar, JM Franklin, M Najafzadeh, A Déruaz-Luyet, ... Circulation 139 (25), 2822-2830, 2019 | 209 | 2019 |
| Not all “quality-adjusted life years” are equal CA Marra, SA Marion, DP Guh, M Najafzadeh, F Wolfe, JM Esdaile, ... Journal of clinical epidemiology 60 (6), 616-624, 2007 | 131 | 2007 |
| Economic value of pharmacist-led medication reconciliation for reducing medication errors after hospital discharge M Najafzadeh, JL Schnipper, WH Shrank, S Kymes, TA Brennan, ... Am J Manag Care 22 (10), 654-661, 2016 | 83 | 2016 |
| Cost effectiveness of herpes zoster vaccine in Canada M Najafzadeh, CA Marra, E Galanis, DM Patrick Pharmacoeconomics 27, 991-1004, 2009 | 76 | 2009 |
| Competition and price among brand-name drugs in the same class: a systematic review of the evidence A Sarpatwari, J DiBello, M Zakarian, M Najafzadeh, AS Kesselheim PLoS medicine 16 (7), e1002872, 2019 | 65 | 2019 |
| Future impact of various interventions on the burden of COPD in Canada: a dynamic population model M Najafzadeh, CA Marra, LD Lynd, M Sadatsafavi, JM FitzGerald, ... Public Library of Science 7 (10), e46746, 2012 | 63 | 2012 |
| Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD M Najafzadeh, CA Marra, M Sadatsafavi, SD Aaron, SD Sullivan, ... Thorax 63 (11), 962-967, 2008 | 63 | 2008 |
| Increasing incidence associated with herpes zoster infection in British Columbia, Canada F Marra, M Chong, M Najafzadeh BMC infectious diseases 16, 1-13, 2016 | 62 | 2016 |
| Barriers to integrating personalized medicine into clinical practice: a best–worst scaling choice experiment M Najafzadeh, LD Lynd, JC Davis, S Bryan, A Anis, M Marra, CA Marra Genetics in medicine 14 (5), 520-526, 2012 | 57 | 2012 |
| Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer H Mamiya, RK Tahara, SM Tolaney, NK Choudhry, M Najafzadeh Annals of Oncology 28 (8), 1825-1831, 2017 | 56 | 2017 |
| Economic evaluation of dose–response resistance training in older women: a cost-effectiveness and cost-utility analysis JC Davis, CA Marra, MC Robertson, KM Khan, M Najafzadeh, MC Ashe, ... Osteoporosis international 22, 1355-1366, 2011 | 51 | 2011 |
| From trial to target populations—calibrating real-world data M Najafzadeh, S Schneeweiss N Engl J Med 376 (13), 1203-1205, 2017 | 49 | 2017 |
| Barriers for integrating personalized medicine into clinical practice: a qualitative analysis M Najafzadeh, JC Davis, P Joshi, C Marra American Journal of Medical Genetics Part A 161 (4), 758-763, 2013 | 48 | 2013 |
| Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality E D’Andrea, DJ Ahnen, DA Sussman, M Najafzadeh Cancer medicine 9 (2), 824-836, 2020 | 43 | 2020 |
| Cost-effectiveness of using a molecular diagnostic test to improve preoperative diagnosis of thyroid cancer M Najafzadeh, CA Marra, LD Lynd, SM Wiseman Value in Health 15 (8), 1005-1013, 2012 | 42 | 2012 |
| Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information M Sadatsafavi, N Bansback, Z Zafari, M Najafzadeh, C Marra Value in Health 16 (2), 438-448, 2013 | 41 | 2013 |
| Using the incremental net benefit framework for quantitative benefit–risk analysis in regulatory decision-making—a case study of alosetron in irritable bowel syndrome LD Lynd, M Najafzadeh, L Colley, MF Byrne, AR Willan, MJ Sculpher, ... Value in Health 13 (4), 411-417, 2010 | 41 | 2010 |
